Should I Buy CING? CING 2026 Analysis

Should You Buy Cingulate Inc (CING) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

6.050

1 Day change

-2.89%

52 Week Range

7.920

Analysis Updated At

2026/02/20

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Cingulate Inc. (CING) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators show no clear bullish trend, and the financial performance remains weak with negative EPS and net income. Additionally, there are no significant positive catalysts or trading signals to suggest immediate upside potential.

Technical Analysis

The MACD is negatively expanding (-0.118), RSI is neutral at 44.267, and moving averages are converging, indicating no clear trend. The stock is trading below the pivot level (6.654), with key support at 5.741 and resistance at 7.567. Overall, the technical outlook is neutral to slightly bearish.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

and net income (-$7.34M).

Financial Performance

In Q3 2025, revenue remained at $0 (0% YoY growth), net income improved to -$7.34M (up 77.94% YoY), and EPS dropped to -1.35 (-42.31% YoY). The company continues to operate at a loss with no revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

3 Analyst Rating

Wall Street analysts forecast CING stock price to rise

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 6.230

Low

Averages

27.33

High

Current: 6.230

Low

Averages

27.33

High

Roth Capital

Boobalan Pachaiyappan

Buy

downgrade

$17 -> $16

AI Analysis

2025-11-18

Reason

Roth Capital

Boobalan Pachaiyappan

Price Target

$17 -> $16

AI Analysis

2025-11-18

downgrade

Buy

Reason

Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it caught up with Cingulate management to discuss Q3 results. At a high level, the company is ratcheting up its CTx-1301 U.S. pre-commercialization efforts through its Indegene partnership, the analyst tells investors in a research note. The firm expects CTx-1301 approval by May 31, 2026.

Roth Capital

NULL

Buy

upgrade

$10 -> $17

2025-10-14

Reason

Roth Capital

Price Target

$10 -> $17

2025-10-14

upgrade

NULL

Buy

Reason

Roth Capital raised the firm's price target on Cingulate to $17 from $10 and keeps a Buy rating on the shares. The FDA's acceptance of Cingulate's NDA package suggests that the agency is likely comfortable with the safety-efficacy characteristics of CTx-1301 in ADHD patients, the analyst tells investors in a research note. The lack of Ad Comm, a PDUFA date that is at least 2 months ahead of Roth's expectations, a potential broad label to all ADHD patients, and importantly, the stellar approval record of all ADHD stimulants, are all good reasons to buy Cingulate stock, the firm added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CING

Unlock Now

CING Should I Buy

CING Should I Buy

Should You Buy Cingulate Inc (CING) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch